BREAKING
Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 13 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 14 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 15 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago Earnings Summary: Zymeworks (ZYME) Q4 FY25 net loss widens 13 hours ago Earnings Summary: A snapshot of Smith+Nephew’s (SNN) Q4 2025 report 14 hours ago Earnings Summary: Norwegian Cruise Line (NCLH) Q4 FY25 revenue rises 6% 15 hours ago Earnings Summary: Highlights of Calumet’s (CLMT) Q4 2025 earnings report 4 days ago Zoom Communications Q4 2025 Earnings Results 4 days ago Agilent Q1 Revenue Rises 7%, Net Income Declines 5 days ago Synopsys Q1 2026 Earnings Results 5 days ago Key highlights from J.M. Smucker’s (SJM) Q3 2026 earnings results 5 days ago Hormel Foods (HRL) Q1 2026 Earnings: Key financials and quarterly highlights 5 days ago Key metrics from Lowe’s (LOW) Q4 2025 earnings results 6 days ago
MRK

Merck & Co, inc

$MRK NYSE Apr 29, 2021 BMO Q1 2021

Investor Toolbox

Listen to Call

Watch or listen to the earnings call recording.

Open Webcast

Read Transcript

Transcript not yet available.

View Infographic

Infographic not yet available.

Earnings History

View past quarters and earnings trends.

View History

MRK Coverage

Event Merck & Co., Inc. (MRK) KEYTRUDA (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer Feb 27, 2026 Event Merck & Co., Inc. (MRK) KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery Feb 27, 2026 Event Merck & Co., Inc. (MRK) Sec Form 10K Feb 26, 2026 Transcript Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript Feb 4, 2026 Transcript Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript Jan 22, 2026 Transcript Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript Jan 22, 2026 News Key highlights from Merck’s (MRK) Q3 2025 earnings results Oct 30, 2025 News Infographic: How Merck (MRK) performed in Q3 2024 Oct 31, 2024